1
|
Mohn F, Scheffler K, Ackers J, Weimer A, Wegner F, Thieben F, Ahlborg M, Vogel P, Graeser M, Knopp T. Characterization of the clinically approved MRI tracer resotran for magnetic particle imaging in a comparison study. Phys Med Biol 2024; 69:135014. [PMID: 38870999 DOI: 10.1088/1361-6560/ad5828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2024] [Accepted: 06/13/2024] [Indexed: 06/15/2024]
Abstract
Objective.The availability of magnetic nanoparticles (MNPs) with medical approval for human intervention is fundamental to the clinical translation of magnetic particle imaging (MPI). In this work, we thoroughly evaluate and compare the magnetic properties of an magnetic resonance imaging (MRI) approved tracer to validate its performance for MPI in future human trials.Approach.We analyze whether the recently approved MRI tracer Resotran is suitable for MPI. In addition, we compare Resotran with the previously approved and extensively studied tracer Resovist, with Ferrotran, which is currently in a clinical phase III study, and with the tailored MPI tracer Perimag.Main results.Initial magnetic particle spectroscopy (MPS) measurements indicate that Resotran exhibits performance characteristics akin to Resovist, but below Perimag. We provide data on four different tracers using dynamic light scattering, transmission electron microscopy, vibrating sample magnetometry measurements, MPS to derive hysteresis, point spread functions, and a serial dilution, as well as system matrix based MPI measurements on a preclinical scanner (Bruker 25/20 FF), including reconstructed images.Significance.Numerous approved MNPs used as tracers in MRI lack the necessary magnetic properties essential for robust signal generation in MPI. The process of obtaining medical approval for dedicated MPI tracers optimized for signal performance is an arduous and costly endeavor, often only justifiable for companies with a well-defined clinical business case. Resotran is an approved tracer that has become available in Europe for MRI. In this work, we study the eligibility of Resotran for MPI in an effort to pave the way for human MPI trials.
Collapse
Affiliation(s)
- Fabian Mohn
- Institute for Biomedical Imaging, Hamburg University of Technology, Hamburg, Germany
- Section for Biomedical Imaging, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Konrad Scheffler
- Institute for Biomedical Imaging, Hamburg University of Technology, Hamburg, Germany
- Section for Biomedical Imaging, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Justin Ackers
- Fraunhofer IMTE, Fraunhofer Research Institution for Individualized and Cell-based Medical Engineering, Lübeck, Germany
| | - Agnes Weimer
- Fraunhofer IMTE, Fraunhofer Research Institution for Individualized and Cell-based Medical Engineering, Lübeck, Germany
- Institute of Physical Chemistry, University of Hamburg, Hamburg, Germany
| | - Franz Wegner
- Institute for Interventional Radiology, University of Lübeck, Lübeck, Germany
| | - Florian Thieben
- Institute for Biomedical Imaging, Hamburg University of Technology, Hamburg, Germany
- Section for Biomedical Imaging, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Mandy Ahlborg
- Fraunhofer IMTE, Fraunhofer Research Institution for Individualized and Cell-based Medical Engineering, Lübeck, Germany
| | - Patrick Vogel
- Department of Experimental Physics 5 (Biophysics), University of Würzburg, Würzburg, Germany
| | - Matthias Graeser
- Fraunhofer IMTE, Fraunhofer Research Institution for Individualized and Cell-based Medical Engineering, Lübeck, Germany
- Institute of Medical Engineering, University of Lübeck, Lübeck, Germany
| | - Tobias Knopp
- Institute for Biomedical Imaging, Hamburg University of Technology, Hamburg, Germany
- Section for Biomedical Imaging, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Fraunhofer IMTE, Fraunhofer Research Institution for Individualized and Cell-based Medical Engineering, Lübeck, Germany
| |
Collapse
|
2
|
Baki A, Wiekhorst F, Bleul R. Advances in Magnetic Nanoparticles Engineering for Biomedical Applications-A Review. Bioengineering (Basel) 2021; 8:134. [PMID: 34677207 PMCID: PMC8533261 DOI: 10.3390/bioengineering8100134] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Revised: 09/16/2021] [Accepted: 09/27/2021] [Indexed: 12/12/2022] Open
Abstract
Magnetic iron oxide nanoparticles (MNPs) have been developed and applied for a broad range of biomedical applications, such as diagnostic imaging, magnetic fluid hyperthermia, targeted drug delivery, gene therapy and tissue repair. As one key element, reproducible synthesis routes of MNPs are capable of controlling and adjusting structure, size, shape and magnetic properties are mandatory. In this review, we discuss advanced methods for engineering and utilizing MNPs, such as continuous synthesis approaches using microtechnologies and the biosynthesis of magnetosomes, biotechnological synthesized iron oxide nanoparticles from bacteria. We compare the technologies and resulting MNPs with conventional synthetic routes. Prominent biomedical applications of the MNPs such as diagnostic imaging, magnetic fluid hyperthermia, targeted drug delivery and magnetic actuation in micro/nanorobots will be presented.
Collapse
Affiliation(s)
- Abdulkader Baki
- Fraunhofer Institute for Microengineering and Microsystems IMM, Carl-Zeiss-Straße 18-20, 55129 Mainz, Germany;
| | - Frank Wiekhorst
- Physikalisch-Technische Bundesanstalt, Abbestraße 2-12, 10587 Berlin, Germany;
| | - Regina Bleul
- Fraunhofer Institute for Microengineering and Microsystems IMM, Carl-Zeiss-Straße 18-20, 55129 Mainz, Germany;
| |
Collapse
|
3
|
Baki A, Löwa N, Remmo A, Wiekhorst F, Bleul R. Micromixer Synthesis Platform for a Tuneable Production of Magnetic Single-Core Iron Oxide Nanoparticles. NANOMATERIALS (BASEL, SWITZERLAND) 2020; 10:E1845. [PMID: 32942715 PMCID: PMC7560047 DOI: 10.3390/nano10091845] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/07/2020] [Revised: 09/09/2020] [Accepted: 09/10/2020] [Indexed: 01/11/2023]
Abstract
Micromixer technology is a novel approach to manufacture magnetic single-core iron oxide nanoparticles that offer huge potential for biomedical applications. This platform allows a continuous, scalable, and highly controllable synthesis of magnetic nanoparticles with biocompatible educts via aqueous synthesis route. Since each biomedical application requires specific physical and chemical properties, a comprehensive understanding of the synthesis mechanisms is not only mandatory to control the size and shape of desired nanoparticle systems but, above all, to obtain the envisaged magnetic particle characteristics. The accurate process control of the micromixer technology can be maintained by adjusting two parameters: the synthesis temperature and the residence time. To this end, we performed a systematic variation of these two control parameters synthesizing magnetic nanoparticle systems, which were analyzed afterward by structural (transmission electron microscopy and differential sedimentation centrifugation) and, especially, magnetic characterization methods (magnetic particle spectroscopy and AC susceptibility). Furthermore, we investigated the reproducibility of the microtechnological nanoparticle manufacturing process compared to batch preparation. Our characterization demonstrated the high magnetic quality of single-core iron oxide nanoparticles with core diameters in the range of 20 nm to 40 nm synthesized by micromixer technology. Moreover, we demonstrated the high capability of a newly developed benchtop magnetic particle spectroscopy device that directly monitored the magnetic properties of the magnetic nanoparticles with the highest sensitivity and millisecond temporal resolution during continuous micromixer synthesis.
Collapse
Affiliation(s)
- Abdulkader Baki
- Devision Energy and Chemical Technology, Fraunhofer Institute for Microengineering and Microsystems IMM, Carl-Zeiss-Straße 18-20, 55129 Mainz, Germany
| | - Norbert Löwa
- Physikalisch-Technische Bundesanstalt, 8.2 Biosignals, Abbestraße 2-12, 10587 Berlin, Germany
| | - Amani Remmo
- Physikalisch-Technische Bundesanstalt, 8.2 Biosignals, Abbestraße 2-12, 10587 Berlin, Germany
| | - Frank Wiekhorst
- Physikalisch-Technische Bundesanstalt, 8.2 Biosignals, Abbestraße 2-12, 10587 Berlin, Germany
| | - Regina Bleul
- Devision Energy and Chemical Technology, Fraunhofer Institute for Microengineering and Microsystems IMM, Carl-Zeiss-Straße 18-20, 55129 Mainz, Germany
| |
Collapse
|